Vnitr Lek 1991, 37(9-10):761-767

[Multicenter study with gliquidone in type 2 diabetes mellitus].

A Kreze, J Vozár, P Rázus, A Lacko, Z Málek, Z Putz: Endokrinologický ústav, Lubochna.

Klíčová slova: Adult; Aged; Diabetes Mellitus, Type 2, blood, ; Female; Humans; Hypoglycemic Agents, adverse effects, ; Male; Middle Aged; Sulfonylurea Compounds, adverse effects,

The effectiveness and tolerance of the new sulphonyl urea antidiabetic gliquidone (commercial name Glurenorm) was tested by three-month administration of this preparation in a group of 39 type 2 diabetics. Gliquidone proved a medium-strength beta-cytotropic antidiabetic preparation. As to side-effects, the authors noted only dyspepsia in one patient (2.5%). Symptomatic hypoglycaemia did not develop in any of the patients. In the subgroup of six patients with diabetic nephropathy the indicators of renal functions did not deteriorate. In a sub-group of 6 patients with concurrent hepatopathy the originally elevated gamma-glutamyl transpeptidase activity receded. The authors confirmed thus the good tolerance of gliquidone in diabetes associated with nephropathy and diabetes with hepatopathy.

Keywords: Adult; Aged; Diabetes Mellitus, Type 2 /blood/; Female; Humans; Hypoglycemic Agents /adverse effects/; Male; Middle Aged; Sulfonylurea Compounds /adverse effects/

Zveřejněno: 1. září 1991 Zobrazit citaci

Kreze A, Vozár J, Rázus P, Lacko A, Málek Z, Putz Z. [Multicenter study with gliquidone in type 2 diabetes mellitus]. Vnitr Lek. 1991;37(9-10):761-767.

Sdílet...

Stáhnout citaci